At the Eisai-sponsored tea symposium during the 27th Malaysian Urological Conference at Shangri-La Kuala Lumpur, Professor Osamu Yokoyama highlighted the advantages of silodosin (Urief®, Eisai Inc.) in relieving lower urinary tract symptoms associated with benign prostate hyperplasia.
Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly used to treat osteoarthritis and rheumatoid arthritis to reduce joint pain and improve joint function. Dr Sazzli Kasim provides his viewpoint on how the current understanding on cardiovascular safety of NSAIDs should be taken into account when determining optimal analgesic strategies for patients with arthritis.
In March 2018, sublingual fentanyl citrate (SLF; Abstral®, Menarini) was made available in Malaysia. SLF is a rapid-onset opioid (ROO) indicated for the management of breakthrough cancer pain (BTcP) episodes in patients that are opioid-tolerant. In July 2018, Menarini organized an expert meeting, aptly named Malaysian Collaborative Meeting of Pain Specialists to Improve Oncology Management (MY-COMPASSION), comprising of key figures in anaesthesiology, palliative care and oncology to discuss current insights into local BTcP management. Below are highlights from the meeting.
Dr. Jeffrey Ross, Dr. Rohit Lal, Prof. Alwin Krämer, Dr. Rebecca Dent, Prof. Rafal Dziadziuszko, 20190124070000
Comprehensive genomic profiling (CGP) has emerged as a key driving force behind personalized cancer care. With the wealth of data available with CGP, medical oncologists now have in their armamentarium a tool that could enable them to provide patients with the optimum treatment. At a Roche Foundation Medicine-sponsored symposium held at the 2018 European Society of Medical Oncology (ESMO) Congress in Munich, Germany, a panel of experts reviewed key data on CGP, with a focus on the treatment of advanced cancers.
In an era of antimicrobial resistance, newer agents are urgently needed. Ceftaroline, a broad spectrum cephalosporin approved for the treatment of community-acquired pneumonia (CAP) and complicated skin and soft tissue infections (cSSTI) is a step forward towards addressing this need. MIMS Anti-Infectives interviewed Dr Asok Kurup, an infectious disease physician practising at the Mount Elizabeth Medical Centre in Singapore, to provide some insights into the role of ceftaroline for the treatment of these conditions.
In conjunction with the launch of QV Intensive with Ceramides (Ego Pharm), the important role of ceramides in themanagement of atopic dermatitis (AD) was highlighted by two distinguished speakers, Dr Agnes Heng of KPJ and Pantai Hospital Ipoh, as well as Dr Fabrizio Spada of Ego Pharmaceuticals, Australia.
At the recent 34th Annual Congress of the Malaysian Society of Nephrology, Dr Kyriaki Stamatelou reviewed the role of alfacalcidol (One-Alpha®; LEO Pharma) – a vitamin D analogue – in the prevention and management of secondary hyperparathyroidism (SHPT) in chronic kidney disease (CKD).
Dr. Choo Gim Hooi, Assoc Prof. Pattarapong Makarawate, Dr. Krisada Sastravaha, 20181217100000
Coronary artery disease (CAD) is a leading cause of mortality and morbidity globally and its burden is expected to increase due to the rising prevalence of risk factors such as hypertension, diabetes, and dyslipidaemia. In conjunction with the 23rd ASEAN Federation of Cardiology Congress held in Bangkok, Thailand, Menarini organized a lunch symposium and product theatre to discuss the significance of optimal medical therapy (OMT) in the management of stable CAD, with a focus on the role of ranolazine (Ranexa®).
At the 3rd National Pain Free Conference held at Putrajaya, Dr Ho Kok Yuen spoke on the role of nonsteroidal anti-inflammatory drugs (NSAIDs) in the management of osteoarthritis (OA) and important considerations when using NSAIDs, especially among patients with risk factors for NSAID toxicity.
Use of mirabegron in the treatment of men with overactive bladder (OAB) appears to effectively alleviate urgency and storage symptoms, but not reduce the frequency of micturition episodes, according to data from the MIRACLE study.